More about Cinderella Therapeutics Research Corporation (CTR.C)

CTR.C takes its directives from the Cinderella Therapeutics Foundation. The foundation owns all CTR.C shares and forms its board of directors. A request for the development of a new stepchild drug or therapy will be reviewed by the foundation together with CTR.C and advisors chosen by the foundation and the inventors of the stepchild drug or therapy. CTR.C receives approved projects and will constitute a working party/consortium for implementation of the project. This includes finding the appropriate medical investigators and specialists; writing a study protocol; obtaining sufficient amounts of the drug and of sufficiently high quality for completion of the proposed study; and obtaining approval from a research ethics committee (in the Netherlands known as METC, or Medisch Ethische Toetsings Commissie). All consortium members will have a vote in project or policy decisions. CTR.C will provide the consortium with data management and general assistance. Results will be published as soon as possible in open-access biomedical journals. CTR.C is structured to obtain high quality data on stepchild drugs/therapies quickly and efficiently by means of a business-like approach and organization. When positive results are obtained, CTR.C will have the sole right to make licensing or royalty agreements with external companies willing to scale-up the production of the new drug/therapies and providing it to users accredited by CTR.C. The price of the new drug/therapy will have a socially acceptable price and profit margin. When CTR.C makes a profit on such transactions it will channel all its profit back into the foundation. The funds owned by the foundation can only be used for the fulfilment of the mission of the foundation: the development of new stepchild drugs/therapies.


 

The general director of the Cinderella Therapeutics Research Corporation is Jan W.M. Visser Ph.D.
Dr. Visser is a biophysicist, has worked at the Radiobiological Institute of TNO, at Los Alamos National Laboratory, and at the New York Blood Center. He was Senior Vice-President of Scientific Research at ViaCell, Inc in Boston, MA, USA.